Fellowship · Phoenix, AZ
Sponsored by Mayo Clinic College of Medicine and Science
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 424 citations · Christina Wu
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Lancet (London, England) · 2023 · 424 citations · Tanios Bekaii-Saab
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 239 citations · Christina Wu
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
The New England journal of medicine · 2023 · 448 citations · Tanios Bekaii-Saab
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Blood · 2025 · 135 citations · Saurabh Chhabra
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.
The New England journal of medicine · 2025 · 109 citations · Tanios Bekaii-Saab
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
The New England journal of medicine · 2025 · 100 citations · Christina Wu
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 271 citations · Tanios Bekaii-Saab